Rilmenidine

• UNSPSC Description:

  Rilmenidine, an innovative antihypertensive agent, is an orally active, selective I1 imidazoline receptor agonist. Rilmenidine is an alpha 2-adrenoceptor agonist. Rilmenidine induces autophagy. Rilmenidine acts both centrally by reducing sympathetic overactivity and in the kidney by inhibiting the Na+/H+ antiport. Rilmenidine modulates proliferation and stimulates the proapoptotic protein Bax thus inducing the perturbation of the mitochondrial pathway and apoptosis in human leukemic K562 cells[1][2][3].

• Target Antigen:

  Adrenergic Receptor; Apoptosis; Autophagy; Imidazoline Receptor

• Type:

  Reference compound

• Related Pathways:

  Apoptosis;Autophagy;GPCR/G Protein;Neuronal Signaling

• Applications:

  Cancer-programmed cell death

• Field of Research:

  Cancer; Cardiovascular Disease

• Assay Protocol:

  https://www.medchemexpress.com/rilmenidine.html

• Purity:

  99.0

• Solubility:

  10 mM in DMSO

• Smiles:

  C1(NC(C2CC2)C3CC3)=NCCO1

• Molecular Weight:

  180.25

• References & Citations:

  [1]Reid JL. Rilmenidine: a clinical overview. Am J Hypertens. 2000;13(6 Pt 2):106S-111S.|[2]Srdic-Rajic T, et al. Rilmenidine suppresses proliferation and promotes apoptosis via the mitochondrial pathway in human leukemic K562 cells. Eur J Pharm Sci. 2016;81:172-180.|[3]Rose C, et al. Rilmenidine attenuates toxicity of polyglutamine expansions in a mouse model of Huntington's disease. Hum Mol Genet. 2010;19(11):2144-2153.

• Shipping Conditions:

  Blue Ice

• Storage Conditions:

  -20°C (Powder, sealed storage, away from moisture and light)

• Clinical Information:

  Launched

• CAS Number:

  54187-04-1